Novartis Investigative Site

Neyagawa, Osaka 5720838

0 studies enrolling now · 2 studies all time

What they study most

Chronic Spontaneous Urticaria

Studies at this site

• An Extension Study of Long-term Efficacy, Safety and Tolerability of Remibrutinib in Chronic Spontaneous Urticaria Patients Who Completed Preceding Studies With Remibrutinib — Running, not enrolling
• Study of Efficacy and Safety of Ligelizumab in Chronic Spontaneous Urticaria Patients Who Completed a Previous Study With Ligelizumab — Stopped early